



## KNR Constructions Limited.

Date: 09<sup>th</sup> February 2024

Ref: KNRCL/SD/2024/675&676

To, The Manager BSE Limited, P J Towers, Dalal Street, Fort, Mumbai – 400001 Scrip code: 532942	To, The Manager, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Scrip Code: KNRCON
--	---

Dear Sir/Madam,

**Sub: Submission of newspaper publication**

**Ref: Reg. 30 of SEBI (LODR) Regulations, 2015**

We refer to the above captioned subject, we herewith submit to the exchanges newspaper publication of audited financial results for the quarter ended 31<sup>st</sup> December 2023 published in Financial Express and Nava Telangana.

This is for the information and records of the Exchange, please.

Thanking you,

Yours truly

For KNR Constructions Limited

**HARITHA** Digitally signed by  
HARITHA VARANASI  
**VARANASI** Date: 2024.02.09  
11:33:19 +05'30'

Haritha Varanasi

Company Secretary

Regd.Office : 'KNR House',3rd & 4th Floor, Plot No.114,Phase-I,Kavuri Hills,  
Hyderabad -500 033 Phone.:+91-40-40268759 ,40268761/ 62, Fax : 040- 40268760 ,

E-mail : [info@knrcl.com](mailto:info@knrcl.com), Web : [www.knrcl.com](http://www.knrcl.com)

CIN: L74210TG1995PLC130199



This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of offer dated 09<sup>th</sup> January, 2024 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE") and the Securities and Exchange Board of India ("SEBI").

## GENPHARMASEC LIMITED

CIN: L24231MH1992PLC323914

Our Company was originally incorporated as "Adi Rasayan Limited" a private limited company vide a Certificate of Incorporation dated 16<sup>th</sup> November, 1992, issued by the Registrar of Companies, Gujarat, Dabra & Nagar Haveli under the provisions of the Companies Act, 1956. Subsequently, the name of our Company was changed to "Generic Pharmasec Limited" and a fresh certificate of incorporation dated 27<sup>th</sup> November, 2018 consequent upon change of name was issued by the Registrar of Companies, Ahmedabad. Thereafter, the name of our Company was further changed to "Genpharmasec Limited" and a fresh certificate of incorporation dated 25<sup>th</sup> October, 2021 consequent upon change of name was issued by the Registrar of Companies, Mumbai. For further details in relation to our Company, please refer to the section titled "General Information" beginning on page 50 of this Letter of offer.

Registered Office: Office No. 104 & 105 1<sup>st</sup> Floor, Gundecha Industrial Premises Co-op Soc. Ltd., Akurli Road, Kandivali East, Mumbai City MH - 400101 | Tel: No. +91-86555 50242

E-mail: [compliance@genpharmasec.com](mailto:compliance@genpharmasec.com) | Website: [www.genpharmasec.com](http://www.genpharmasec.com)

Contact Person: Ms. Heta Deepak Shah, Company Secretary & Compliance Officer

PROMOTERS OF OUR COMPANY: MR. RAJESH SADHWANI AND MRS. SNEHA SADHWANI

### THE ISSUE

ISSUE OF UPTO 27,68,59,850 EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH ("EQUITY SHARES") OF GENPHARMASEC LIMITED ("GENPHARMA" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 1.75 PER EQUITY SHARE (INCLUDING PREMIUM OF ₹ 0.75 PER EQUITY SHARE) ("ISSUE PRICE") FOR AN AGGREGATE AMOUNT NOT EXCEEDING ₹ 4,845.05 LAKHS TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. TUESDAY, 09<sup>th</sup> JANUARY, 2024 (THE "ISSUE"). THE ISSUE PRICE IS 1.75 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 123 OF THE LETTER OF OFFER.

### ATTENTION INVESTORS

#### NOTICE TO THE READER ("NOTICE") – CORRIGENDUM CUM ADDENDUM TO LETTER OF OFFER DATED JANUARY 09, 2024 AND CORRIGENDUM CUM ADDENDUM DATED JANUARY 20, 2024

This notice should be read in conjunction with the LOF and Corrigendum cum addendum to Letter of Offer dated January 09, 2024 and Corrigendum cum addendum dated January 20, 2024 filed by the Company with the Stock Exchange and SEBI and the ALOF and CAF that have been sent to the Eligible Equity Shareholders of the Company. The Eligible Equity Shareholders are requested to please note the following:

#### RIGHTS ISSUE PERIOD EXTENDED

ISSUE CLOSING DATE (OLD)	ISSUE CLOSING DATE (NEW)
FRIDAY, 09 <sup>th</sup> FEBRUARY, 2024	TUESDAY, 13 <sup>th</sup> FEBRUARY, 2024

This is to inform the Eligible Shareholders of the Company that the date of closure of the Rights Issue, which opened on Tuesday, January 23, 2024 and scheduled to close on Friday, February 09, 2024 has now been extended from Friday, February 09, 2024 to Tuesday, February 13, 2024, by the Rights Issue Committee in its Meeting held on February 08, 2024 in order to provide an opportunity to shareholders to exercise their rights in the Rights Issue.

Accordingly, the last date of submission of the duly filled in CAF (along with the amount payable on application) is Tuesday, February 13, 2024. Equity Shareholders of the Company who are entitled to apply for the Rights Issue as mentioned above are requested to take note of the Issue Closure Date as Tuesday, February 13, 2024.

This Corrigendum cum addendum shall be available on the respective websites of the Stock Exchange at [www.bseindia.com](http://www.bseindia.com) and the website of the Company at [www.genpharmasec.com](http://www.genpharmasec.com).

Accordingly, there is no change in the LOF, CAF and ALOF dated January 09, 2024 except for modification in the Issue Closing date. Change in Issue closing date resultant change in indicative time table of post issue activities on account of extension of issue closing date.

INVESTORS MAY PLEASE NOTE THE LETTER OF OFFER, ABRIDGED LETTER OF OFFER, COMMON APPLICATION FORM, CORRIGENDUM CUM ADDENDUM TO LETTER OF OFFER DATED JANUARY 20, 2024 SHALL BE READ IN CONJUNCTION WITH THIS CORRIGENDUM CUM ADDENDUM.

For Genpharmasec Limited  
On Behalf of the Board of Directors

Date: February 08, 2024  
Place: Mumbai

Ms. Heta Deepak Shah  
Company Secretary and Compliance officer

**Disclaimer:** Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer dated January 09, 2024 with the Securities and Exchange Board of India and BSE. The Letter of Offer is available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), website of Stock Exchange where the Equity Shares are listed i.e. BSE at [www.bseindia.com](http://www.bseindia.com). Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 31 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.

AdBaz



## Mrs. Bectors Food Specialities Limited

Regd. Office: Theing Road, Phillaur, Jalandhar-144410

Corporate Identity Number (CIN): L74899PB1995PLC033417, PAN: AABCM9495K

Website: [www.bectorfoods.com](http://www.bectorfoods.com), Email: [atul.sud@bectorfoods.com](mailto:atul.sud@bectorfoods.com)

Extract of Un-audited Consolidated Financial Results for the Quarter & Nine months ended 31st December, 2023  
(Rs. in million except per share data)

Sr No	Particulars	Quarter ended		Nine months ended		Year ended	
		31.12.2023 (Un-Audited)	30.09.2023 (Un-Audited)	31.12.2022 (Un-Audited)	31.12.2022 (Un-Audited)		31.03.2023 (Audited)
1	Total Income from Operations	4,335.40	4,176.86	3,709.84	12,299.30	10,236.26	13,741.62
2	Net Profit Before Tax for the period	463.48	499.61	369.86	1,430.75	836.79	1,207.03
3	Net Profit after tax for the period	346.12	372.83	277.75	1,067.45	624.20	900.74
4	Total Comprehensive Income for the period [Comprising Profit for the period and Other Comprehensive Income (after tax)]	345.94	372.71	279.79	1,067.00	630.29	900.19
5	Paid-up Equity Share Capital (Face value of Rs.10/- per share)	588.17	588.17	588.17	588.17	588.17	588.17
6	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet at 31st March 2023						4,855.01
7	Earnings Per Share (in Rs) (non annualised):						
	Basic:	5.89	6.33	4.72	18.15	10.61	15.31
	Diluted:	5.89	6.33	4.72	18.15	10.61	15.31

Extract of Un-audited Standalone Financial Results for the Quarter & Nine months ended 31st December, 2023  
(Rs. in million except per share data)

Sr No	Particulars	Quarter ended		Nine months ended		Year ended	
		31.12.2023 (Un-Audited)	30.09.2023 (Un-Audited)	31.12.2022 (Un-Audited)	31.12.2022 (Un-Audited)		31.03.2023 (Audited)
1	Total Income from Operations	4,045.86	3,884.65	3,446.49	11,441.46	9,502.03	12,759.30
2	Net Profit Before Tax for the period	403.24	439.31	316.35	1,245.06	697.17	1,020.01
3	Net Profit after tax for the period	301.02	327.55	237.87	928.42	520.94	762.53
4	Total Comprehensive Income for the period [Comprising Profit for the period and Other Comprehensive Income (after tax)]	300.87	327.41	239.84	927.99	526.83	761.95
5	Paid-up Equity Share Capital (Face value of Rs.10/- per share)	588.17	588.17	588.17	588.17	588.17	588.17
6	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet at 31st March 2023						4,512.01
7	Earnings Per Share (in Rs) (non annualised):						
	Basic:	5.11	5.57	4.05	15.78	8.86	12.96
	Diluted:	5.11	5.57	4.05	15.78	8.86	12.96

**Notes:**

- The above standalone and consolidated unaudited financial results for the quarter and nine months ended 31st December, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors on 8th February, 2024. These results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015.
- The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on unaudited financial results, visit financial information section of our website [www.bectorfoods.com](http://www.bectorfoods.com) and financials results at corporate section at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).
- The Group is engaged in the single operating segment "Food products".
- The above is an extract of the detailed format of unaudited Financial Results for the quarter and nine months ended 31st December, 2023 filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015. The full format of the abovesaid financial results are available on the Stock Exchange websites, [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and on the Company's website [www.bectorfoods.com](http://www.bectorfoods.com).

For and on behalf of Board of Directors of  
Mrs. Bectors Food Specialities Limited

Place: Phillaur  
Date: 08.02.2024

Anoop Bector  
Managing Director

## MIRC ELECTRONICS LIMITED

Regd. Office : Onida House, G-1, MIDC, Mahakali Caves Road, Andhori (East), Mumbai - 400093.  
CIN No. : L32300MH1981PLC023637, Website : [www.onida.com](http://www.onida.com)

Extract of statement of Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2023

Particulars	Quarter ended		Nine months ended		Year ended	
	31.12.2023		31.12.2022		31.03.2023	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income from operations	29,502	19,604	27,292	67,702	88,751	111,267
Net Profit / (Loss) for the period before Tax	155	(643)	(256)	(1,110)	(515)	(1,247)
Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary items)	155	(643)	(256)	(1,110)	(515)	(1,247)
Net Profit / (Loss) for the period after Tax	155	(643)	(256)	(1,110)	(515)	(1,247)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	157	(642)	(261)	(1,105)	(529)	(1,240)
Paid Up Equity Share Capital (face value of Re.1/- each)	2,311	2,311	2,311	2,311	2,311	2,311
Reserves (excluding Revaluation Reserves)						16,773
Earnings Per Share (of Re.1/- each) (for continuing and discontinued operations) -						
Basic:	0.07	(0.28)	(0.11)	(0.48)	(0.22)	(0.54)
Diluted:	0.07	(0.28)	(0.11)	(0.48)	(0.22)	(0.54)

Notes :

- The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the websites of BSE and NSE at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively and on Company's website at [www.onida.com](http://www.onida.com).
- The above results as reviewed by the Audit Committee, have been taken on record at the meeting of the Board of Directors held on 8th February, 2024

for MIRC ELECTRONICS LIMITED

Sd/-  
G. L. Mirchandani  
Chairman & Managing Director  
DIN : 00026654

Place : Mumbai  
Date : 8th February, 2024

## KNR CONSTRUCTIONS LIMITED

Regd. Office : KNR House , 3rd & 4th Floor, Plot No: 114, Phase-I, Kavuri Hills, Hyderabad - 500033. Ph: 040 -40268759 / 61/ 62, Fax: 040-40268760; website : [knrl.com](http://knrl.com); E-mail : [investors@knrl.com](mailto:investors@knrl.com) CIN: L74210TG1995PLC130199

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

Sl. No.	Particulars	STANDALONE						CONSOLIDATED					
		Quarter Ended 31-12-2023 (Unaudited)	Quarter Ended 30-09-2023 (Unaudited)	Quarter Ended 31-12-2022 (Unaudited)	Nine Months ended 31-12-2023 (Unaudited)	Nine Months ended 31-12-2022 (Unaudited)	Year Ended 31-03-2023 (Audited)	Quarter Ended 31-12-2023 (Unaudited)	Quarter Ended 30-09-2023 (Unaudited)	Quarter Ended 31-12-2022 (Unaudited)	Nine Months ended 31-12-2023 (Unaudited)	Nine Months ended 31-12-2022 (Unaudited)	Year Ended 31-03-2023 (Audited)
1	Total income from operations	90,542.51	94,147.10	83,021.23	277,648.29	256,821.09	374,379.62	99,601.47	103,845.28	87,492.63	301,548.29	281,702.73	406,235.97
2	Net Profit / (Loss) for the period (before Tax, Exceptional items#)	11,362.33	13,442.78	10,785.50	39,501.42	39,362.73	56,710.86	16,409.08	17,711.17	12,346.28	50,778.20	43,294.86	62,021.38
3	Net Profit / (Loss) for the period before tax (after Exceptional items#)	11,362.33	13,442.78	24,582.11	39,501.42	53,159.34	70,507.47	16,409.08	17,711.17	18,530.77	50,778.20	49,479.35	68,205.87
4	Net Profit / (Loss) for the period after tax (after Exceptional items#)	8,553.49	9,986.03	16,183.51	29,565.39	37,022.88	49,883.32	13,583.89	14,254.42	10,742.04	40,626.47	29,819.74	44,022.11
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	8,562.34	10,002.36	16,167.82	29,603.16	36,975.81	49,933.67	13,578.16	14,290.92	10,811.69	41,206.37	29,720.74	43,991.76
6	Equity Share Capital	5,624.70	5,624.70	5,624.70	5,624.70	5,624.70	5,624.70	5,624.70	5,624.70	5,624.70	5,624.70	5,624.70	5,624.70
7	Other Equity	-	-	-	-	-	267,802.82	-	-	-	-	-	271,445.29
8	Earnings Per Share (of Rs. 2/- each) (for continuing and discontinued operations) -												
	1. Basic: (Rs.)	3.04*	3.55*	5.75*	10.51*	13.16*	17.74	4.96*	5.24*	3.76*	15.08*	11.05*	16.29
	2. Diluted: (Rs.)	3.04*	3.55*	5.75*	10.51*	13.16*	17.74	4.96*	5.24*	3.76*	15.08*	11.05*	16.29

\*Not Annualized

NOTES:

- The above Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on February 08, 2023.
- Figures for the previous year/period have been regrouped/re-classified to conform to the figures of the current period.
- The above is an extract of the detailed format of Quarterly / Nine months ended Financial Results filed with the Stock Exchange under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine months ended Financial Results is available on the Stock Exchange website namely, BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)), and on the Company's website: [www.knrl.com](http://www.knrl.com)

Place : Hyderabad  
Date : 08-02-2024

## AARTI INDUSTRIES LIMITED

Regd. Off.: Plot Nos.801, 801/23, Phase -III, G.I.D.C. Estate, Vapi-396195, Dist. Valsad, Gujarat  
Head. Off.: 71, Udyog Kshetra, 2nd Floor, Mulund-Goregaon Link Road, Mulund (W), Mumbai- 400 080  
Website: [www.aarti-industries.com](http://www.aarti-industries.com); Email: [investorrelations@aarti-industries.com](mailto:investorrelations@aarti-industries.com); CIN: L24110GJ1984PLC007301

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

Sr. No.	Particulars	Standalone						Consolidated					
		Quarter ended		9 Months Ended		Year ended	Quarter ended		9 Months Ended		Year ended		
		31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-22		31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22		31-Dec-22	31-Mar-23
1	Total Income from Operations (Net)	1,732	1,450	1,635	4,586	4,926	6,565	1,740	1,454	1,668	4,608	4,964	6,619
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	116	82	159	271	478	613	117	82	160	270	476	611
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	116	82	159	271	478	613	117	82	160	270	476	611
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	124	91	135	286	398	546	124	91	137	285	397	545
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	125	88	133	289	361	511	126	87	128	289	354	495
6	Paid-up Equity Share Capital (Face Value of Rs. 5/- each)	181	181	181	181	181	181	181	181	181	181	181	181
7	Reserves (excluding Revaluation Reserve)						4,740						4,739
8	Net												



